Efficacy and safety of tislelizumab in the treatment of advanced non-small cell lung cancer：a meta-analysis
- VernacularTitle:替雷利珠单抗治疗晚期非小细胞肺癌有效性和安全性的Meta分析
- Author:
Yanxue WANG
1
;
Xiaotong LIAN
1
;
Ziying LIANG
1
;
Xinyi GUO
1
;
Qiuyi YUAN
1
;
Jinni WANG
1
;
Yixuan QIN
1
;
Xiaolian DING
1
;
Gang LIANG
2
Author Information
1. College of Pharmacy，Guangxi Medical University，Nanning 530021，China
2. College of Pharmacy，Guangxi Medical University，Nanning 530021，China;Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation，Nanning 530021，China
- Publication Type:Journal Article
- Keywords:
tislelizumab;
advanced non-small cell lung
- From:
China Pharmacy
2025;36(19):2454-2459
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically evaluate the efficacy and safety of tislelizumab in the treatment of advanced non- small cell lung cancer （NSCLC）. METHODS Computerized searches were conducted in PubMed， Embase， the Cochrane Library， CNKI， Wanfang and other Chinese and English databases to collect randomized controlled trials （RCTs） on tislelizumab for advanced NSCLC. The search period was from the establishment of the databases to December 2024. After strictly screening the literature， extracting data and conducting quality evaluations in accordance with the inclusion and exclusion criteria， a meta-analysis was performed using RevMan 5.3 and Stata 16.0 software. RESULTS A total of 18 RCTs involving 2 337 patients were included， with 1 283 in the experimental group and 1 054 in the control group. The meta-analysis results showed that the objective response rate [RR＝1.61， 95%CI （1.48， 1.75）， P＜0.000 01]， disease control rate [RR＝1.21， 95%CI （1.13， 1.29）， P＜0.000 01]， progression free survival [HR＝0.55， 95%CI （0.45， 0.66）， P＜0.000 01]， and overall survival [HR＝0.78， 95%CI（0.62， 0.97）， P＝0.03] were significantly better in the experimental group than in the control group. There was no statistically significant difference in the incidence of adverse reactions between the two groups [RR＝1.00， 95%CI （0.73， 1.37）， P＝1.00]； among the common adverse reactions， only the incidence of liver function impairment was significantly higher in the experimental group than in the control group [RR＝1.30， 95%CI （1.10， 1.54）， P＜0.01]. CONCLUSIONS Tislelizumab in combination with chemotherapy or targeted drugs significantly improves the efficacy in patients with advanced NSCLC without increasing the risk of adverse reactions overall. However， liver function should be closely monitored during treatment.
